Hitaxa Metmin-Spray (Mometasone Furoate)

Hitaxa Metmin‑Spray is indicated for the treatment of several nasal inflammatory conditions.

• Allergic rhinitis (seasonal or perennial) to reduce nasal congestion, itching, and sneezing.
• Nasal polyps to shrink polyp size and improve nasal airflow.
• Non‑infectious rhinosinusitis as an adjunct to other therapies.
• Post‑operative nasal care to minimize swelling after sinus surgery.
• Chronic nasal inflammation where a corticosteroid spray is appropriate.

• Mometasone furoate acts as a potent glucocorticoid receptor agonist in the nasal epithelium. Binding to intracellular receptors triggers transcriptional changes that suppress the production of inflammatory cytokines, prostaglandins, and leukotrienes. This reduces vascular permeability and immune cell infiltration, leading to decreased edema and mucus formation in the nasal passages. The localized action limits systemic exposure while providing sustained anti‑inflammatory effect within the nasal mucosa.

Adverse reactions to Hitaxa Metmin‑Spray are generally mild, but serious events can occur rarely.

Common

• Nasal irritation or burning sensation.
• Headache.
• Epistaxis (nosebleeds).
• Unpleasant taste or throat irritation.

Serious

• Nasal septal perforation.
• Severe allergic reaction such as anaphylaxis or facial swelling.
• Elevated intraocular pressure or glaucoma.

Before using Hitaxa Metmin‑Spray, consider the following precautions to ensure safe and effective therapy.

• Avoid chronic use without medical supervision; long‑term exposure may affect the nasal mucosa.
• Do not use if you have a known hypersensitivity to mometasone furoate or other corticosteroids.
• Use cautiously in patients with recent nasal surgery or trauma.
• Monitor for signs of ocular hypertension or glaucoma during prolonged therapy.
• Discuss use during pregnancy or lactation with a healthcare professional.
• Keep the spray tip clean to prevent contamination.

Hitaxa Metmin‑Spray may interact with other medications administered intranasally or systemically; consider the following guidance.

Avoid

• Concurrent use of other intranasal corticosteroids, which can increase the risk of local side effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole) that may raise systemic mometasone levels.

Use with caution

• Systemic antifungal agents that affect CYP3A4 metabolism.
• Nasal decongestants, as combined use may cause nasal dryness or irritation.
• Immunosuppressive drugs, because additive effects on immune response are possible.